8-K Announcements
6Material company update
Dec 5, 2025·SEC
Material company update
Oct 15, 2025·SEC
Material company update
Oct 9, 2025·SEC
Carisma Therapeutics, Inc.(CARM)Earnings, Financials & Key Ratios
CARM•NASDAQ
$0.01
Price updated Jul 7, 2026
AboutCarisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.Show more
- Revenue$20M+31.6%
- EBITDA-$59M+31.5%
- Net Income-$60M+30.4%
- EPS (Diluted)-1.46+43.6%
- Gross Margin-203.96%+48.6%
- EBITDA Margin-299.64%+48.0%
- Operating Margin-316.72%+46.7%
- Net Margin-308.05%+47.1%
CARM Price & Volume
Carisma Therapeutics, Inc. (CARM) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Growth Trajectory
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall
Key Thesis Takeaways
- Carisma Therapeutics faces a precarious financial outlook as its reliance on lumpy, milestone-based revenue fails to offset the high costs of autologous cell therapy development.
- The company's rapid depletion of its cash reserves, which fell from $83.1 million in 2023Q3 to just $2.8 million by 2025Q3, suggests an urgent need for dilutive capital raises to sustain operations.
- Investors should remain cautious given the negative equity position of -$867.0 thousand and the structural inability to achieve consistent, scalable profitability.
Verdict Logic
the company's cash runway is nearly exhausted with only $2.8 million in cash remaining as of 2025Q3, creating an imminent risk of significant shareholder dilution to fund ongoing clinical trials.
CARM Growth Metrics
Carisma Therapeutics, Inc. (CARM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.23%
5 Years-
3 Years-9.57%
TTM159.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM112.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM112.82%
Return on Capital
10 Years-51.33%
5 Years-69.24%
3 Years-104.57%
Last Year-141.24%
Peers Comparison
Key metrics vs top competitors for Carisma Therapeutics, Inc. (CARM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.01 | $242.7K | -0.00 | 31.59% | -308.05% | — | — | |
| $14.66 | $1.36B | -10.32 | 144.57% | -151.12% | — | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $4.12 | $1.15B | -4.29 | — | — | -161.87% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — |
Compare CARM vs Peers
Carisma Therapeutics, Inc. (CARM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CARM SEC Filings & Documents
Carisma Therapeutics, Inc. (CARM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CARM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CARM Frequently Asked Questions
Carisma Therapeutics, Inc. (CARM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Carisma Therapeutics, Inc.'s revenue?
Carisma Therapeutics, Inc. (CARM) reported $52.6M in revenue for fiscal year 2024.
How fast is Carisma Therapeutics, Inc. growing?
Carisma Therapeutics, Inc. (CARM) grew revenue by 31.6% over the past year. This is strong growth.
Is CARM profitable?
Yes, Carisma Therapeutics, Inc. (CARM) is profitable, generating $8.0M in net income for fiscal year 2024 (-308.1% net margin).
Dividend & Returns
What is Carisma Therapeutics, Inc.'s free cash flow?
Carisma Therapeutics, Inc. (CARM) had negative free cash flow of $22.4M in fiscal year 2024, likely due to heavy capital investments.